Standout Papers

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metasta... 2014 2026 2018 2022 328
  1. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study (2014)
    Timothy Price, Marc Peeters et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 5 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Mapping the effectiveness and risks of GLP-1 receptor agonists
2025 Standout
Exploring treatment options in cancer: tumor treatment strategies
2024 Standout
1 intermediate paper

Works of Kathy Zhang being referenced

Outcomes and Disposition of Patients After Case Cancellation on Day of Surgery for Reasons Attributed to Medical or Anesthetic Care: A Retrospective Cohort Analysis
2022
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
2014 Standout

Author Peers

Author Last Decade Papers Cites
Kathy Zhang 583 213 291 232 39 1.3k
Markus Raderer 583 260 370 208 61 1.4k
SP Stenning 383 454 517 417 39 1.3k
Yasuo Ejima 369 198 386 103 49 1.3k
Wilfried J. Graveland 816 187 522 336 27 1.7k
Gary V. Burton 719 196 327 126 67 1.4k
S.L. Tucker 555 144 416 229 39 1.4k
Stefania Scarpino 347 77 267 367 50 1.3k
Anthony J. Piro 397 201 329 62 41 1.1k
C.F. Hess 405 432 350 151 49 1.1k
Yeu‐Tsu N. Lee 609 187 338 65 56 1.0k

All Works

Loading papers...

Rankless by CCL
2026